Skip to main content

Research Repository

Advanced Search

Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy

Bowerman

Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy Thumbnail


Authors



Abstract

Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including lifespan, weight and key molecular networks in skeletal muscle. Our work highlights the potential of multiple and parallel data driven approaches for the development of novel treatments for use in combination with SMN restoration therapies.

Citation

Bowerman. (2021). Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI insight, 1-24. https://doi.org/10.1172/jci.insight.149446

Acceptance Date May 17, 2021
Publication Date Jul 8, 2021
Journal JCI Insight
Print ISSN 2379-3708
Pages 1-24
DOI https://doi.org/10.1172/jci.insight.149446
Publisher URL https://insight.jci.org/articles/view/149446

Files







You might also like



Downloadable Citations